Articles by Justin Neway - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Justin Neway

Justin Neway


Justin Neway, PhD, is executive vice-president and chief science officer at Aegis Analytical Corporation.

Articles
Improving Technology Transfer
November 1, 2012

This article focuses on the growing need for effective data management in the life sciences industry—especially among smaller pharmaceutical manufacturers.

Biosimilars Increase the Need for IT to Reduce Variability
August 17, 2011

Using information technology tools to enhance process understanding helps reduce variability that can affect speed to market.

Intelligence Platforms Can Strengthen Relationships with Contractors
July 21, 2010

With the right technology tools, the sponsor organization and the contract manufacturer can have self-service, on-demand, and scheduled access to all manufacturing, quality, and process-development data.

Process Intelligence Is Critical to the Pharmaceutical Enterprise
December 16, 2009

Process intelligence helps users gain a specific understanding of their manufacturing processes and how to control their sources of variability.

Bridging the Development–Manufacturing Gap to Achieve QbD and PAT
February 18, 2009

To implement QbD and reduce business risks, teams should begin QbD collaboration early during process development.

Better Process Understanding Improves Quality, Lowers Risk
June 2, 2006

Predictable outcomes lead to greater manufacturing efficiency and speed time to value.

Filling the Void: PAT in a Connected Manufacturing Environment
October 2, 2003

The author brings attention to the connectivity problems among various data-gathering systems and discusses the drivers and benefits of change, including PAT.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here